Food Allergy Innovations
While there are millions of people managing food allergies around the world, you can count the number of recommended treatments and therapies on one hand. Innovation around food allergies has been stagnant for years, but recently, a number of startups have emerged that offer allergy sufferers hope that avoidance won't be the only solution for long. From Silicon Valley to the University of Chicago, scientists and entrepreneurs - some of whom live with life-threatening allergies themselves - there are exciting new innovations that could simplify and save lives.
For decades, EpiPen has dominated the auto-injector market, but many patients would welcome new options. Learn about potential alternatives that promise affordability, portability and ease of use.
This Boston startup is working to develop an epinephrine auto-injector that’s 40 percent smaller than current auto-injectors, simple to use, and has a long shelf life. This new auto-injector stores the drug in a temp-stable, dry form until it’s needed. Upon activation, the device rapidly and automatically mixes the dry drug to form a solution when the cap is removed. According to Windgap’s CEO, the improved temperature stability means that if their epinephrine auto-injector is left in a hot car on a sunny day, it won’t have to be thrown away. Windgap’s product will be submitted for FDA review in 2018.
Researchers in Florida are working to develop a dissolvable pill that, when placed under the tongue, will reportedly deliver epinephrine as effectively as an auto-injector. While this product may be more portable, affordable and easier to use than an injector, it has yet to be tested on patients experiencing anaphylactic shock. Currently, they are still awaiting FDA approval to begin testing and trials.
Since the 2015 recall of AUVI-Q, Kaleo took back the license to manufacture the popular auto-injector and invested in new systems to ensure "accurate, reliable and consistent delivery" from the product. In February 2017, AUVI-Q returned to the market with an unprecedented affordability plan. AUVI-Q is the same portable size and still features the unique voice prompt system that offers users step-by-step instructions. For more information, check out Spokin's AUVI-FAQ and learn How To Get AUVI-Q For $O.
Products + Gadgets
From pocket-sized food testers to high-tech bracelets for kids, discover inventions that are providing practical solutions to everyday problems.
Abigail Barnes, the co-founder and CEO of Allergy Amulet, has suffered from several life-threatening food allergies since childhood. After teaming up with a chemistry professor at Dartmouth who also has food allergies, this line of sleek, wearable food allergen and ingredient detection devices was developed. Their USB-sized reader and disposable test strips will detect peanuts initially, with plans to expand to dairy and other common allergens and ingredients shortly thereafter. Pre-orders are set to begin in 2017. The reader will cost somewhere between $100 and $250, and disposable test strips will cost between $1 and $3 each.
This pocket-sized gluten sensor, which will be shipping out to consumers in the spring of 2017, can detect minuscule amounts of gluten in foods in less than 3 minutes. They plan to offer devices that test for peanuts and milk in the near future. Currently, Nima starter kits cost $279.
Allergy bracelets are getting a high-tech upgrade, thanks to AllerGuarder. This colorful children’s wrist band creates a virtual defense shield around the wearer using Bluetooth technology and a free mobile app. First, select a color and a charm that lists the allergen. Then, invite friends, family, school faculty and other caregivers to download the app on their smartphones. When a child wearing this bracelet is nearby, adults will get an alert on their phones that details the child’s allergens and any other information the parent chooses to share, reminding caregivers to stay vigilant when a parent isn’t present. AllerGuarder is available now on Amazon for $80.95 and additional charms can be purchased on their website.
Introducing infants to potential allergens can be stressful for any mom or dad, especially if that baby is classified as “high risk.” Check out three new companies striving to simplify parents’ lives.
This health and wellness company hopes to put a stop to food allergies before they start. CEO Ashley Dombkowski, Ph.D. and co-founder Dr. Kari Nadeau seem uniquely qualified for the task. Ashley was the Chief Business Officer at 23andMe as well as an active investor and serial entrepreneur in the healthcare industry. Dr. Nadeau is a pediatrician and director of the Sean N. Parker Center for Allergy Research at Stanford University and the woman behind the breakthrough oral immunotherapy (OIT) trials. Together, they are developing ways to work allergens into children’s lives at a very early age, and while specific products are still in development, there may be both edible and topical options.
Since the LEAP (Learning Early About Peanut) study found that an early introduction of nuts into an infant’s diet could prevent an allergy from developing, parents - and companies - have been searching for safe, effective solutions. This system enables parents to gradually introduce peanuts to babies as young as 5 months. The powder, which is organic and allergist recommended, can be mixed into baby food over the course of seven days. Introduction kits are currently sold at $25.
Using precise doses of liquified peanut protein, Aralyte’s goal is to introduce a common allergen into the diets of babies as young as 4 months old as conveniently as possible. This liquid can be mixed into breast milk, formula or pureed foods without presenting a choking hazard. A two-week supply is now available for $29 on Amazon.
Brilliant minds across the country are currently running tests and trials, hoping to someday improve the lives of allergy sufferers. Find out what’s on the horizon.
Scientists at the University of Chicago, starting out in the research lab, are developing a drug to treat childhood food allergies. Their breakthrough discoveries about the gut’s complex microbiome - a population of trillions of bacteria living inside all of us - and its ability to create a barrier that stops allergens from entering the bloodstream, led to the creation of ClostraBio. While new medications are still a year or two from clinical trials, they’ve already identified a difference in the gut bacteria of babies who had cow’s milk allergies and infants who did not.
Aimmune Therapeutics Inc.
Aimmune’s lead product candidate, AR101, seeks to safely and reliably protect peanut-allergic children and adults in cases of accidental exposure to peanut. People who receive this promising treatment will sprinkle gradually increasing amounts of AR101 on their food over a set amount of time, with the goal of increasing the amount of peanut protein an individual can tolerate. The FDA has already granted AR101 “Breakthrough Therapy Designation” and “Fast Track Designation” statuses, which may help expedite AR101’s availability to patients and allergy clinics throughout the United States. Aimmune is also reportedly working on similar treatments for other food allergies.
Some day soon, immunotherapy may be as simple as brushing your teeth. Intrommune Therapeutics is striving to develop an oral mucosal immunotherapy (OMIT) product that delivers small extracts of common food allergens via a prescription toothpaste that is fully-functional for regular dental hygiene. This therapy is designed to become part of your everyday routine, and over an extended period of time, desensitize people to certain foods.